Lipid-based formulations and versatile liquid-filled hard capsule (LFHC) technology are core strengths of Lonza. LFHC technology has a proven track record in addressing a range of complex formulation challenges inclusive of solubility/bioavailability and low dose/highly potent API issues. We provide integrated services for LFHC development and manufacturing from proof-of-concept studies through clinical trial manufacture and commercialization.  

Liquid-filled hard capsule technology provides an advanced dosage form for liquid and semi-solid formulations. LFHC technology has been utilized in bringing new molecules to market and repositioning existing molecules for improved performance or new indications. Our product development teams utilize LFHC across a range of applications, which result in innovative dosage forms that are leak-proof, airtight, and impermeable to moisture, oxygen and light. 

Over the last 25 years, we have built an unrivaled track record in the design, development and manufacture of specialized liquid-filled hard capsule drug products.

QBD Applications for Lipid-Based Pharmaceutical Products

Lonza produces >25 commercial biopharmaceutical liquid-filled hard capsule products

liquid-filled hard capsules: proven applications


Liquid-filled hard capsule (LFHC) technology is used to address a broad array of formulation challenges, often incorporating a variety of biopharmaceutically-approved lipid and non-lipid excipients.  Formulation flexibility is a hallmark of LFHC formulations and we have successfully utilized the technology to achieve:

  • Bioavailability enhancement
  • Dose uniformity 
  • Safe formulation of highly potent API 
  • Improved API stability 
  • Combination products 
  • Colonic delivery
  • Abuse deterrence

Additionally, LFHC technology can be used for rapid screening of compounds and accelerated development timelines for compounds requiring an LBF approach. Its relatively simple manufacturing process, which has been refined through decades of process engineering, offers a shortened development cycle for CTM manufacture and scale-up.

Our focus on science and engineering has led to the development of proprietary equipment and processing techniques, which in turn provide greater efficiency, reliability and productivity of LFHC manufacture.

The choice between capsule banding versus capsule fusion technology is application and customer-specific. Capsule banding, where a visible band of gelatin or HPMC is applied around the capsule joint, is one approach often favored for client branding, dose identification, or for tamper-evidence considerations. The second option is our proprietary LEMS® (Liquid Encapsulation Micro-Spray) or “Fusion” Technology, which utilizes the application of a fine micro-spray of sealing solution around the joint and between the capsule body and cap. Both sealing approaches are fully validated with commercial precedence in ensuring product quality and robust, leak-free performance.

related content

BA Enhancement
The depth of our bioavailability enhancement offering makes us a leader in addressing drug solubility and dissolution rate issues.
Colonic Delivery
We combine our expertise in encapsulation and targeted delivery to the gastro-intestinal track to achieve effective colonic delivery.
Formulation and Product Development
We provide integrated preformulation, formulation and product development services to our biopharmaceutical customers using a broad range of enabling technologies to address formulation challenges.
Low Dose and High Potent Applications
Liquid and semi-solid fill technologies are proven approaches for safely handling HPAPI and achieving low dose content uniformity. HPAPI is a core focus area of Lonza and we provide fully integrated services from drug substance to specialized oral solid dosage forms.
SimpliFiH™ Solutions
We can provide integrated drug substance and drug product services for preclinical studies and phase I clinical trials.
Soft Gelatin Technology
Softgels provide an important dosage technology that can be highly beneficial in addressing a wide array of formulation challenges, such as bioavailability enhancement and low dose/HPAPI applications including hormones.